Corporate Social Responsibility
Adhere To The Principle Of Sustainable Development To Create A Better Life
AI Full-Chain Intelligent Upgrade: Health Yuan Starts Efficiency Innovation
Published Time：
2025-04-30
In the wave of intelligent transformation of the global pharmaceutical industry, artificial intelligence has become a core force driving the transformation of various industries. The pharmaceutical field is no exception, with AI reshaping the industrial landscape with unprecedented depth and breadth. As a leading domestic enterprise in the respiratory field, HealthGen has keenly captured this trend, actively using AI to empower the company's innovative development, comprehensively reshaping the entire life cycle management of the pharmaceutical industry, and exploring innovative paths for high-quality development in the face of fierce market competition.
AI is deeply integrated into the R&D system, Accelerating the innovation drug R&D process
In 2024, the global AI field ushered in explosive growth, with technological breakthroughs and market applications promoting each other, profoundly changing economic and social life. HealthGen decisively began its layout at the beginning of the year, fully promoting the innovative application of AI technology in various business segments of the company, and accelerating the intelligent and digital transformation of internal processes. In the key area of innovative drug R&D, the company introduced a globally leading AI model and completed the deployment and application of the "full-blooded" version of DeepSeek-R1 671B, becoming one of the first pharmaceutical companies in China to introduce a hundreds-of-billions-parameter AI model into its core business.
With the help of these globally leading AI models, HealthGen has comprehensively improved R&D efficiency in aspects such as target identification, molecular design, and molecular screening. In the early stages of drug R&D, AI technology has carried out work such as activity prediction, toxicity assessment, and prescription screening, optimizing the R&D path, effectively shortening the R&D cycle, improving R&D efficiency and success rate, and laying a solid foundation for the rapid launch of innovative drugs.
Intelligent manufacturing upgrades the production system, Building a solid moat for drug quality
In addition to the R&D link, HealthGen also deeply integrates AI into production quality control, precision marketing, and functional management, achieving full-chain digital upgrading. In the field of production quality control, the company has built an intelligent central hub based on the Feishu platform, integrating data flows from key nodes such as procurement, warehousing, production, and quality inspection, using AI to optimize process stability, ensuring that the entire drug production process complies with international and national quality standards, and improving production efficiency while ensuring product quality.
Currently, among the company's existing 18 production bases, HealthGen Haibin has adopted KUKA robots to achieve the intelligent automation of the entire inhalation preparation process, improving efficiency while reducing production accidents, and has become one of the world's leading production bases for inhalation preparations.
In the respiratory field, actively responding to national policies on the prevention and control of chronic respiratory diseases, vigorously developing respiratory chronic disease drugs, and addressing the clinical needs of patients. With the help of advanced production tools such as AI, improving operating efficiency from R&D, clinical trials, production to sales, and enhancing corporate competitiveness.
Data-driven precision marketing, Building a full-cycle intelligent ecological chain
In terms of precision marketing, the marketing team relies on an AI-driven customer portrait system to deeply mine and analyze data, accurately positioning high-potential markets. At the same time, using AI to improve the level of digital marketing, breaking down communication barriers between doctors, patients, hospitals, and the company, forming a high-efficiency closed loop, and enhancing market competitiveness. In functional management, the company builds a cross-departmental cooperation mechanism, using AI to achieve real-time data sharing and intelligent decision-making, improving personnel work efficiency, and providing strong support for the company's efficient operation.
As a pioneer in the domestic inhalation preparation field, HealthGen has formed a certain scale of innovation system and launched a series of products with independent intellectual property rights. Currently, the company has more than 20 innovative drug products under research, of which 10 have entered clinical phase II or later; among them, the respiratory field R&D pipeline has covered more than 10 Class 1 innovative drugs, such as the new influenza drug maparsivir and TSLP monoclonal antibody, consolidating the company's position among innovative pharmaceutical companies.
Looking forward to 2025, against the backdrop of a complex and changing global economic situation and fierce market competition, with the dual support of AI technology's deep empowerment of the entire life cycle of the pharmaceutical industry and the continuous efforts of innovative policies, HealthGen is expected to show greater growth potential in the capital market, create long-term value for investors, provide better treatment options for patients, and continue to promote the high-quality development of China's pharmaceutical industry.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.